Pherecydes Pharma Extends Its Intellectual Property in China With a First Patent Granted for Its anti-Pseudomonas aeruginosa Phages in This Territory

Regulatory News: Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections

Related Keywords

China ,Australia ,Japan ,United States ,Hong Kong ,Israel ,France ,French ,Chinese ,Arthur Rouill ,Pherecydes Pharma ,Dusan Oresansky Olivier Bricaud ,Regulatory News ,Charles Fanneau De La Horie ,Executive Board ,French National Agency ,Oresansky Olivier Bricaud ,Pherecydes ,Dharma ,Xtends ,Intellectual ,Property ,Ith ,First ,Patent ,Granted ,Anti ,Pseudomonas ,Aeruginosa ,Phages ,This ,Territory ,